Previous 10 | Next 10 |
Immix Biopharma (NASDAQ:IMMX) said it has received Board's approval on Monday to repurchase up to $1M of its common shares. As of Apr. 15, 2022, the company had about 13.9M shares outstanding. "We are confident that with the $24.2 million gross proceeds raised in our recent IPO, ImmixBio is s...
LOS ANGELES, May 09, 2022 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (Nasdaq: IMMX) (“ImmixBio”, “Company”, “We” or “Us”), a biopharmaceutical company pioneering Tissue-Specific Therapeutics (TSTx) TM targeting oncology and immuno-d...
Gainers: Sunshine Biopharma (SBFM) +132%. Dingdong Limited (DDL) +29%. System1 (SST) +27%. FG Financial Group (FGF) +25%. Missfresh (MF) +21%. BT Brands (BTBD) +20%. Longeveron (LGVN) +18%. Compass Therapeutics (CMPX) +18%. Allego (ALLG) +17%. Nam Tai Property (NTP) +15%. Losers: IMARA (IMRA)...
Gainers: Sunshine Biopharma (SBFM) +181%. Nano-X Imaging (NNOX) +15%. Arcus Biosciences (RCUS) +13%. Cue Biopharma (CUE) +11%. Dermata Therapeutics (DRMA) +6%. Losers: IMARA (IMRA) -35%. GBS (GBS) -15%. Precipio (PRPO) -13%. Cassava Sciences (SAVA) -10%...
The IMMX Milestone Day Event is viewable at www.immixbio.com/Apr2022MilestoneDay Management discussed financial position, milestones, and new opportunities presented by current market volatility ImmixBio plans to commence 2 clinical trials in 2022 LOS ANGELES, April 05, 2022...
Management plans to discuss current financial position, milestones, and new opportunities presented by current market volatility With $24.2 million gross proceeds from its December 2021 IPO, ImmixBio plans to commence 2 clinical trials in 2022 A photo accompanying this announcem...
IMX-120 utilizes proprietary, humanized antibody fragment to selectively silence disease-causing, overactive inflammatory bowel immune cells ImmixBio anticipates filing an IND for IMX-120 in 2023 The inflammatory bowel disease market is expected to reach $21.4 billion by 2...
Gainers: IceCure Medical (NASDAQ:ICCM) +16%. Atossa Therapeutics (NASDAQ:ATOS) +15%. G Medical Innovations (NASDAQ:GMVD) +11%. Exscientia (NASDAQ:EXAI) +10%. Immix Biopharma (NASDAQ:IMMX) +10%. Losers: Dermata Therapeutics (NASDAQ:DRMA) -...
Peloton Interactive PTON +32% Amazon buying Peloton would give it several benefits, including Prime boost: Truist. IceCure Medical (NASDAQ:ICCM) +17%. Origin Agritech (NASDAQ:SEED) +15% issues 2022 guidance of 300% revenue growth. Spirit Airlines SAVE +11% on Q4 results. H...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Short-squeeze stocks continue to be hot with traders and we’re going over five candidates that investors will want to watch today. Source: Alextype/Shutterstock.com Today’s list of short-squeeze candid...
News, Short Squeeze, Breakout and More Instantly...
LOS ANGELES, CA, July 25, 2024 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us”, “IMMX”) (Nasdaq: IMMX), a clinical-stage biopharmaceutical company trailblazing cell therapies in AL Amyloidosis and...
Lead site Memorial Sloan Kettering Cancer Center (MSKCC) Timing of milestone in-line with mid-2024 guidance Data from ex-US clinical trial reported at ASGCT 2024 showed a 92% overall response rate LOS ANGELES, July 08, 2024 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“ImmixBio...
A look at the top 10 most actives in the United States NVIDIA Corporation (NVDA) rose 4.6% to $128.28 on volume of 215,349,874 shares Zoomcar Holdings Inc. (ZCAR) rose 34.0% to $0.183 on volume of 204,010,215 shares Maxeon Solar Technologies Ltd. (MAXN) fell 3.5% to $0.1736 on volume of 2...